Beyond tyrosine kinase inhibitors: Combinations and other agents-Reference-Cited by-同舟云学术

Beyond tyrosine kinase inhibitors: Combinations and other agents

Published:2016-09 Issue:3 Volume:29 Page:271-283
ISSN:1521-6926
Container-title:Best Practice & Research Clinical Haematology
language:en
Short-container-title:Best Practice & Research Clinical Haematology

Author:

Cayssials Emilie,Guilhot Francois

Funder

Programme Hospitalier de Recherche Clinique

Ligue Nationale de Recherche Contre le Cancer

Institut National sur le Cancer

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Oncology

Reference86 articles.

1. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood (ASH Annual Meeting Abstracts),2009

2. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

3. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

4. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia;Druker;N Engl J Med,2006

5. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial;Mahon;Lancet Oncol,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives;Cancers;2022-11-09

2. Can increased immunogenicity in chronic myeloid leukemia improve outcomes?;Expert Review of Hematology;2019-03-11

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities

;Drug Design, Development and Therapy;2019-03

4. Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance;Mini-Reviews in Medicinal Chemistry;2019-01-29

5. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?;Seminars in Immunopathology;2018-09-10